NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles

PHASE4TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Infertility
Interventions
DRUG

Contraceptives, Oral

0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.

DRUG

Contraceptive, Vaginal ring

etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day

Trial Locations (1)

H4P 2S4

Clinique Ovo, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Clinique Ovo

INDUSTRY

NCT01638767 - NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles | Biotech Hunter | Biotech Hunter